Filters: Author is Phelps, Michael E [Clear All Filters]
Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment.. Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging. 4(4):283-93.. 2002.
Clinical Value of Neuroimaging in the Diagnosis of Dementia. Sensitivity and Specificity of Regional Cerebral Metabolic and Other Parameters for Early Identification of Alzheimer's Disease.. Clinical positron imaging : official journal of the Institute for Clinical P.E.T. 2(3):119-130.. 1999.
Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study.. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 16(12):999-1009.. 2008.
Differential FDDNP PET patterns in nondemented middle-aged and older adults.. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 17(5):397-406.. 2009.
Effects of a 14-day healthy longevity lifestyle program on cognition and brain function.. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 14(6):538-45.. 2006.
Estrogen use and brain metabolic change in postmenopausal women.. Neurobiology of aging. 26(2):229-35.. 2005.
Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 43(2):253-66.. 2002.
Imaging beta-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization.. Nuclear medicine and biology. 32(4):337-51.. 2005.
Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia.. Archives of general psychiatry. 66(1):81-7.. 2009.
An integrated microfluidic device for large-scale in situ click chemistry screening.. Lab on a chip. 9(16):2281-5.. 2009.
A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens.. Cancer research. 70(15):6128-38.. 2010.
Multimodal Imaging of Alzheimer Pathophysiology in the Brain's Default Mode Network.. International journal of Alzheimer's disease. 2011:687945.. 2011.
Perceived loss of memory ability and cerebral metabolic decline in persons with the apolipoprotein E-IV genetic risk for Alzheimer disease.. Archives of general psychiatry. 63(4):442-8.. 2006.
PET of brain amyloid and tau in mild cognitive impairment.. The New England journal of medicine. 355(25):2652-63.. 2006.
A phenotypic small-molecule screen identifies an orphan ligand-receptor pair that regulates neural stem cell differentiation.. Chemistry & biology. 14(9):1019-30.. 2007.
Serotonin 1A receptors in the living brain of Alzheimer's disease patients.. Proceedings of the National Academy of Sciences of the United States of America. 103(3):702-7.. 2006.
Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly.. Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging. 12(2):218-24.. 2010.